Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2015-05-21 | Reverse | 1:7 |
Lexicon Pharmaceuticals, a Texas-based biopharma founded in 1995, develops oral small molecules like Sotagliflozin and LX9211, with collaborations with Bristol-Myers Squibb and Genentech.
INPEFA (sotagliflozin), approved in 2023, is an oral SGLT1/2 inhibitor indicated to reduce heart failure hospitalization risk, marking Lexicon's transition to a commercial-stage biopharmaceutical company.
Lexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk to develop and commercialize its oral drug candidate, LX9851, for the treatment of obesity and other metabolic disorders. The deal, potentially worth up to $1 billion in milestone payments plus tiered royalties, provided a significant financial boost and external validation of Lexicon's research and development capabilities.
In a decisive strategic shift, Lexicon Pharmaceuticals eliminated its entire commercial organization and reduced its workforce by approximately 60%. This transformation is designed to conserve cash and refocus the company's resources exclusively on advancing its clinical development pipeline, moving away from a commercial-stage biopharma model.
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line results from the pivotal phase 3 SONATA-HCM trial for sotagliflozin in HCM are expected in Q1 2027.
He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 OMER | $18.85 | COMPARE |
 FDMT | $12.86 | COMPARE |
 OCGN | $1.02 | COMPARE |
 FULC | $3.70 | COMPARE |
 BCYC | $3.98 | COMPARE |
 CMPX | $0.99 | COMPARE |
 ADCT | $1.20 | COMPARE |
 NMRA | $0.50 | COMPARE |
